{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cancer+vaccine+plus+immune+adjuvant&page=3",
    "query": {
      "intervention": "Cancer vaccine plus immune adjuvant",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 64,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cancer+vaccine+plus+immune+adjuvant&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cancer+vaccine+plus+immune+adjuvant&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-09T08:35:19.211Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06741072",
      "title": "BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Kidney Disease, Stage 4",
        "Chronic Kidney Disease, Stage 5",
        "EBV-Related Lymphoproliferative Disorder",
        "EBV-Related Malignant Neoplasm",
        "Post-Transplant Lymphoproliferative Disorder"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Dulbecco''s Phosphate-Buffered Saline",
          "type": "DRUG"
        },
        {
          "name": "Peptide Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "QS21",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Ohio State University Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 55,
      "start_date": "2026-06-28",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-02",
      "last_synced_at": "2026-10-09T08:35:19.211Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06741072"
    },
    {
      "nct_id": "NCT00004929",
      "title": "Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "MUC-2-KLH vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "QS21",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 15,
      "start_date": "1999-09",
      "completion_date": "2008-06",
      "has_results": false,
      "last_update_posted_date": "2013-01-31",
      "last_synced_at": "2026-10-09T08:35:19.211Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004929"
    },
    {
      "nct_id": "NCT00849121",
      "title": "Two-Arm Study of a DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) in Patients With Non-Metastatic Castrate-Resistant Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "pTVG-HP with rhGM-CSF",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 17,
      "start_date": "2009-03-16",
      "completion_date": "2014-02-17",
      "has_results": true,
      "last_update_posted_date": "2019-11-21",
      "last_synced_at": "2026-10-09T08:35:19.211Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00849121"
    },
    {
      "nct_id": "NCT00006041",
      "title": "Vaccine Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Fallopian Tube Cancer",
        "Ovarian Cancer",
        "Primary Peritoneal Cavity Cancer"
      ],
      "interventions": [
        {
          "name": "MUC1-KLH conjugate vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MUC1-KLH vaccine/QS21",
          "type": "BIOLOGICAL"
        },
        {
          "name": "QS21",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": null,
      "start_date": "2000-02",
      "completion_date": "2002-02",
      "has_results": false,
      "last_update_posted_date": "2013-06-19",
      "last_synced_at": "2026-10-09T08:35:19.211Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006041"
    },
    {
      "nct_id": "NCT00857545",
      "title": "OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage IA Fallopian Tube Cancer",
        "Stage IA Ovarian Cancer",
        "Stage IB Fallopian Tube Cancer",
        "Stage IB Ovarian Cancer",
        "Stage IC Fallopian Tube Cancer",
        "Stage IC Ovarian Cancer",
        "Stage IIA Fallopian Tube Cancer",
        "Stage IIA Ovarian Cancer",
        "Stage IIB Fallopian Tube Cancer",
        "Stage IIB Ovarian Cancer",
        "Stage IIC Fallopian Tube Cancer",
        "Stage IIC Ovarian Cancer",
        "Stage IIIA Fallopian Tube Cancer",
        "Stage IIIA Ovarian Cancer",
        "Stage IIIA Primary Peritoneal Cancer",
        "Stage IIIB Fallopian Tube Cancer",
        "Stage IIIB Ovarian Cancer",
        "Stage IIIB Primary Peritoneal Cancer",
        "Stage IIIC Fallopian Tube Cancer",
        "Stage IIIC Ovarian Cancer",
        "Stage IIIC Primary Peritoneal Cancer",
        "Stage IV Fallopian Tube Cancer",
        "Stage IV Ovarian Cancer",
        "Stage IV Primary Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Polyvalent Antigen-KLH Conjugate Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Saponin-based Immunoadjuvant OBI-821",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Gynecologic Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 171,
      "start_date": "2010-07",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2017-09-13",
      "last_synced_at": "2026-10-09T08:35:19.211Z",
      "location_count": 46,
      "location_summary": "Mobile, Alabama • Orange, California • Palo Alto, California + 38 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Lewes",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00857545"
    },
    {
      "nct_id": "NCT00003357",
      "title": "Vaccine Therapy Plus QS21 in Treating Women With Breast Cancer Who Have No Evidence of Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "GM2-KLH vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "QS21",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "1998-01",
      "completion_date": "2001-11",
      "has_results": false,
      "last_update_posted_date": "2012-12-13",
      "last_synced_at": "2026-10-09T08:35:19.211Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003357"
    },
    {
      "nct_id": "NCT06949410",
      "title": "HER2 Vaccine for Locally Advanced Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "HER2-positive Breast Cancer"
      ],
      "interventions": [
        {
          "name": "HER2 Vaccine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pravin T.P Kaumaya",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2026-09",
      "completion_date": "2030-03",
      "has_results": false,
      "last_update_posted_date": "2026-08-27",
      "last_synced_at": "2026-10-09T08:35:19.211Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06949410"
    },
    {
      "nct_id": "NCT06963697",
      "title": "Expanded Access To Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors",
      "overall_status": "AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Personalized Synthetic Long Peptide Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Jaime Leandro Foundation for Therapeutic Cancer Vaccines",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2026-01-15",
      "last_synced_at": "2026-10-09T08:35:19.211Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06963697"
    },
    {
      "nct_id": "NCT00773097",
      "title": "Study of the MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Risk for Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "MUC1 - Poly ICLC",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Robert Schoen",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "40 Years to 70 Years"
      },
      "enrollment_count": 46,
      "start_date": "2008-10",
      "completion_date": "2012-10",
      "has_results": true,
      "last_update_posted_date": "2019-01-07",
      "last_synced_at": "2026-10-09T08:35:19.211Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00773097"
    },
    {
      "nct_id": "NCT00616941",
      "title": "Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Epithelial Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Primary Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "NY-ESO-1 OLP4",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NY-ESO-1 OLP4 + Montanide",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NY-ESO-1 OLP4 + Montanide + Poly-ICLC",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Ludwig Institute for Cancer Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 28,
      "start_date": "2008-03",
      "completion_date": "2011-06",
      "has_results": true,
      "last_update_posted_date": "2022-10-12",
      "last_synced_at": "2026-10-09T08:35:19.211Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00616941"
    }
  ]
}